Category: 787618-22-8

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

787618-22-8, Palladium reagents -vvere synthesized following the scheme of Figure 2. Ascintillation vial (J 0 mL), equipped with a magnetic stir bar, was charged vith RuPhos (1.1equiv) or sSPhos (1.1 equiv), Ar–.X (1 equiv), and tetrahydrofuran. Solid [(1,5-COD)Pd(CH2SiMe3)2] (Vinogradova, E. V., et al. Organometallic palladium reagents forcysteine bioconjugation. Nature. 526, 687-691 (2015)) (1 1 equiv) vas added rapidly in oneportion and the resulting solution was stirred for 1 h at 1t. After this time, pentane (3 mL)was added and the resulting mixture was placed into a … 20 C freezer for 2 h. The vial wasremoved from the freezer and, in the air, the resulting precipitate was filtered, washed withpentane (5 x 3 mL), and dried under reduced pressure to afford the oxidative addition complex; Follovving the general procedure, a mixture containing 4-chlorotoluene (6.4 ~LL, 0.054mmol), RuPhos (28 mg, 0.06 mmol), and [(1,5-COD)Pd(CH2SiMe3)2] (25 mg, 0.06 nunol)was stirred at rt in a nitrogen-filled glovebox in cyclohexane (1.5 mL) for 18 h. Generalwork-up afforded A as a grey solid (37 mg, 96%,).

The synthetic route of 787618-22-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; BUCHWALD, Stephen, L.; PENTELUTE, Bradley, L.; ZHANG, Chi; (170 pag.)WO2017/151910; (2017); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

787618-22-8, Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine is a chiral-phosphine-ligands compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

787618-22-8, [Step 4] tert-Butyl 7-methyl-8-(4-methylpiperazin-1-yl)-5-oxo-1,5-dihydro-2H-chromeno[3,4-c]pyridine-3(4H)-carboxylate To a suspension of tert-butyl 7-methyl-5-oxo-8-{[(trifluoromethyl) sulfonyl]oxy}-1,5-dihydro-2H-chromeno[3,4-c]pyridine-3(4H)-carboxylate (5.60 g) in toluene (100 ml), cesium carbonate (5.91 g), chloro-(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium (II)-methyl-t-butyl ether adduct (250 mg), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (141 mg) and 1-methylpiperazine (3.33 ml) were added. The reaction solution was stirred in a nitrogen atmosphere at 110 C. for 8 hours while heating. The reaction solution was diluted with chloroform and a small volume of methanol and filtered with Celite. The reaction solution, to which water and saturated saline were added, was extracted with chloroform and a small volume of methanol. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1-10% methanol/chloroform) to obtain the title compound (4.59 g) as a solid. 1H-NMR (CDCl3) delta: 7.36 (1H, d, J=8.5 Hz), 6.99 (1H, d, J=8.5 Hz), 4.40 (2H, s), 3.72 (2H, t, J=5.8 Hz), 3.02 (4H, t, J=4.6 Hz), 2.88-2.82 (2H, m), 2.66-2.57 (2H, m), 2.38 (6H, s), 1.66-1.59 (2H, m), 1.49 (9H, s). MS (ESI/APCI) m/z: 414 [M+H]+

787618-22-8 Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine 121592071, achiral-phosphine-ligands compound, is more and more widely used in various fields.

Reference£º
Patent; Daiichi Sankyo Company, Limited; Ota, Masahiro; Inoue, Hidekazu; Kawai, Junya; Ohki, Hitoshi; Toki, Tadashi; (25 pag.)US2019/284198; (2019); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

787618-22-8,787618-22-8, Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine is a chiral-phosphine-ligands compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Palladium reagents were synthesized following the scheme of Figure 14 for generalprocedure A. In a nitrogen-filled glovebox, an oven-dried scintillation vial (1 0 mL), whichwas equipped with a magnetic stir bar and fitted with a Teflon screwcap septum, vascharged with RuPhos (2.5 equiv), a dihaloaryl compound (1 equiv) and cydohexane (1.2mL). Solid [(1,5-COD)Pd(CH2Si:Me3)] (2.5 equiv) was added rapidly in one portion and theresulting solution vvas stirred for 16 hat Jt. After this time, pentane (3 mL) was added andthe resulting mixture vas placed into a -20 C freezer for 3 h. The vial was then takenoutside of the glove box, and the resulting precipitate was filtered, washed with pentane (3 X3 mL), and dried under reduced pressure to afford the oxidative addition complex (Figure14)

As the paragraph descriping shows that 787618-22-8 is playing an increasingly important role.

Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; BUCHWALD, Stephen, L.; PENTELUTE, Bradley, L.; ZHANG, Chi; (170 pag.)WO2017/151910; (2017); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

787618-22-8, Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine is a chiral-phosphine-ligands compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

787618-22-8, (r3-1-tBu-indenyl)2(ji-Cl)2Pd2 (3d) (0.300 g, 0.48 mmol) and RuPhos (0.448 g, 0.98 mmol) were added to a 100 mL Schlenk flask and placed under an atmosphere ofnitrogen. THF (20 mL) was added to the flask via cannula. The resulting solution was stirred for 60 minutes, during which time the reaction mixture became homogeneous. The mixture was opened to air and 90% of the solvent was evaporated under reduced pressure. Pentane was added to precipitate solid from solution. A red-orange solid was collected via vacuum filtration. Yield: 0.694 g, 89%.?H NMR (CDC13, 600 MHz): 7.65-7.61 (m, 1H), 7.43-7.36 (m, 2H), 7.26(obscured by solvent, 1H), 7.01 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 7.4 Hz, 1H), 6.83 (t, J = 7.4Hz, 1H), 6.66-6.58 (m, 4H), 6.40 (s, 1H), 4.66 (d, J = 2.5 Hz, 1H), 4.52-4.44 (sept, J = 6.1Hz, 2H), 2.23 (m, 1H), 2.09 (m, 1H), 2.05-1.99 (m, 2H), 1.69-1.62 (m, 5H), 1.56 (s, 9H),1.49-1.43 (m, 5H), 1.33-1.19 (m, 9H), 1.16-0.92 (m, 11H), 0.54 (d, J= 12.2 Hz, 2H)ppm.?3c{?H} NMR (CDC13, 150 MHz): 157.25, 139.13, 137.57, 137.40, 133.08, 129.40, 128.82,126.03, 125.66, 124.14, 120.81, 118.88, 106.47, 71.42, 71.06, 34.54, 34.51, 30.02, 29.98,27.55, 27.44, 26.31, 22.51, 22.45, 22.42 ppm. 3?P{?H} NMR(CDC13, 121 MHz): 57.13 ppm. Anal. Calcd for C43H58C1PdPO2: C, 66.23; H, 7.50; N, 0.00. Found: C, 66.00; H, 7.48; N,

787618-22-8 Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine 121592071, achiral-phosphine-ligands compound, is more and more widely used in various fields.

Reference£º
Patent; YALE UNIVERSITY; HAZARI, Nilay; MELVIN, Patrick; HRUSZKEWYCZ, Damian; (92 pag.)WO2016/57600; (2016); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

787618-22-8, General procedure: After purging with argon, a scintillation vial (10 mL), which was equipped with amagnetic stir bar, was charged with RuPhos (1 equiv), the aryl containing drug or the drugderivative, and [(L5-COD)Pd(CT-iSi~1fe3)] (l. l equiv) dissolved in tetrahydrofuran (THF,0.2 M). The closed vial was purged with argon and stined for 16 h. The resulting precipitatewas tlltered, washed with pentane (3 X 3 mL), and dried under reduced pressure to afford theoxidative addition complex (Figure 3). Other potential aryl containing drugs or drugderivatives are shown in Figure 4.

As the paragraph descriping shows that 787618-22-8 is playing an increasingly important role.

Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; BUCHWALD, Stephen, L.; PENTELUTE, Bradley, L.; ZHANG, Chi; (170 pag.)WO2017/151910; (2017); A2;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

787618-22-8, General procedure: Representative procedure for the preparation of rPdtoptionally substituted (Ri?), allyl)(liqand)(X) complexes: A dry Schlenk tube is charged with the ligand (4.74 mmol) and [(optionally substituted (Ri2)m- allyl)PdCI]2 (2.36 mmol). The tube is evacuated and backfilled with nitrogen a total of three times. 10 mL of anhydrous solvent (such as THF or toluene) is added and the mixture is stirred at room temperature for a period of time (e.g . 20 minutes). Pentane (5 mL) or hexanes is added to fully precipitate the product. The product is collected by vacuum filtration, washed (3 x 10 mL of pentane, or hexanes) and dried under vacuum

The synthetic route of 787618-22-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; JOHNSON MATTHEY PUBLIC LIMITED COMPANY; COLACOT, Thomas; CHOW, Ruishan; JON DEANGELIS, Andrew; WO2015/189554; (2015); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.

787618-22-8, [Step 4] tert-Butyl 8-[(3S)-3,4-dimethylpiperazin-1-yl]-7,10-dimethyl-5-oxo-1,5-dihydro-2H-chromeno[3,4-c]pyridine-3(4H)-carboxylate A suspension of tert-butyl 7,10-dimethyl-5-oxo-8-{[(trifluoromethyl) sulfonyl]oxy}-1,5-dihydro-2H-chromeno[3,4-c]pyridine-3(4H)-carboxylate (1.063 g), cesium carbonate (2.2 g), chloro-(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl] palladium (II)-methyl-t-butyl ether adduct (91 mg), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (52 mg), and (2S)-1,2-dimethylpiperazine (510 mg) in toluene (30 ml) was stirred while heating in a nitrogen atmosphere at 110 C. for 2.5 hours. The reaction solution was diluted with chloroform and a small volume of methanol and an insoluble solid was filtered off and the mother liquid was concentrated. The residue was purified by silica gel column chromatography (4-8% methanol/chloroform) to obtain the title compound (710 mg) as a solid. 1H-NMR (CDCl3) delta: 1.13 (3H, d, J=6.1 Hz), 1.50 (9H, s), 2.29-2.40 (1H, m), 2.33 (3H, s), 2.37 (3H, s), 2.46-2.62 (2H, m), 2.66 (3H, s), 2.87-2.98 (2H, m), 2.99-3.14 (4H, m), 3.58-3.65 (2H, m), 4.40 (2H, s), 6.70 (1H, s). MS (ESI/APCI) m/z: 442 [M+H]+

As the paragraph descriping shows that 787618-22-8 is playing an increasingly important role.

Reference£º
Patent; Daiichi Sankyo Company, Limited; Ota, Masahiro; Inoue, Hidekazu; Kawai, Junya; Ohki, Hitoshi; Toki, Tadashi; (25 pag.)US2019/284198; (2019); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate